Willow GLP-1 Telehealth: Patient Profiles to Avoid and What to Know Before You Sign Up

Who Should Not Use Willow: The Clinical Contraindications

The FDA's prescribing information for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) lists specific absolute and relative contraindications that apply to every prescriber, including telehealth platforms. No matter how convenient a platform is, these contraindications are non-negotiable.

Medullary Thyroid Carcinoma and MEN2

The FDA-approved label for semaglutide carries a boxed warning stating that the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [1]. This warning exists because GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors in rodent studies, and while causation in humans has not been definitively established, the FDA considers the risk sufficient for an absolute contraindication [1].

A telehealth intake form cannot replace the genetic counseling or thyroid ultrasound that a patient with a suspicious family history may need. If you have a first-degree relative with MTC or have been diagnosed with MEN2, you should not enroll in Willow or any GLP-1 platform without first consulting an endocrinologist.

Pregnancy and Breastfeeding

GLP-1 receptor agonists are not recommended during pregnancy. The FDA label for Wegovy (semaglutide 2.4 mg) states that the drug should be discontinued at least two months before a planned pregnancy, because animal studies showed fetal harm at clinically relevant exposures [1]. The American College of Obstetricians and Gynecologists similarly advises against continuing GLP-1 agents during gestation given inadequate human safety data [2].

Women of reproductive age who are actively trying to conceive, currently pregnant, or breastfeeding should not use Willow's GLP-1 services until their prescriber has reviewed the risk-benefit profile in detail.

Prior Acute or Chronic Pancreatitis

The prescribing information for both semaglutide and tirzepatide includes a warning about pancreatitis. Patients who have experienced acute pancreatitis or who carry a diagnosis of chronic pancreatitis should discuss the risk carefully with a physician before starting any GLP-1 agent [1]. A 2022 analysis published in Diabetes Care noted that GLP-1 receptor agonists are associated with a small but measurable increase in acute pancreatitis risk compared to placebo [3].

An asynchronous telehealth intake is not the right venue to triage a patient with pancreatic history. If your records include any pancreatitis diagnosis, flag this explicitly before enrolling.

Active Eating Disorders: A Nuanced but Serious Concern

Patients with active anorexia nervosa or bulimia nervosa require specialist oversight before starting any weight-modifying pharmacotherapy. GLP-1 agonists work partly through appetite suppression and delayed gastric emptying, and in a patient with a restrictive eating disorder, these mechanisms may compound already dangerous caloric restriction [4].

What the Evidence Says

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [5]. That degree of weight loss in a patient with untreated anorexia could be life-threatening. No major GLP-1 trial has enrolled patients with active eating disorders as a primary population, meaning the safety profile in this group is essentially unknown.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends that clinicians screen for eating disorder history before initiating anti-obesity medications and involve a mental health professional when an active disorder is identified [6].

What Willow's Telehealth Model Cannot Do

A short intake questionnaire cannot reliably screen for subclinical restrictive behaviors, binge-purge cycles, or orthorexia. If you are in active treatment for an eating disorder or have been within the past 12 months, you should discuss GLP-1 candidacy with your eating disorder treatment team before using any telehealth GLP-1 platform, Willow included.

Severe Renal or Hepatic Impairment

Renal Considerations

Semaglutide does not require dose adjustment for renal impairment based on current FDA labeling, but the drug has not been studied in patients on dialysis, and nausea-induced dehydration may worsen kidney function in patients with stage 4 or 5 chronic kidney disease [1]. The 2023 FLOW trial (N=3,533) showed that semaglutide reduced the risk of major kidney disease events by 24% in patients with type 2 diabetes and CKD, compared to placebo [7]. However, FLOW enrolled patients with eGFR as low as 20 mL/min/1.73m² under rigorous clinical monitoring that a cash-pay telehealth platform cannot replicate.

Patients with eGFR <30 mL/min/1.73m² should ensure their nephrologist is aware of and actively co-managing any GLP-1 prescription.

Hepatic Considerations

Moderate-to-severe hepatic impairment may alter drug exposure. The tirzepatide label notes limited data in patients with severe hepatic impairment, and clinical caution is recommended [8]. If you carry a diagnosis of Child-Pugh B or C cirrhosis, a telehealth-only prescribing relationship is likely insufficient.

Cardiovascular Contraindications and Cautions

Prior Serious Cardiovascular Events

The SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, compared to placebo [9]. This is a meaningful benefit for the right patient. The wrong patient is one whose cardiologist has imposed specific medication restrictions post-procedure or post-infarction that a telehealth intake form may not capture.

Resting Heart Rate Elevation

GLP-1 receptor agonists consistently raise resting heart rate by approximately 2 to 4 beats per minute in clinical trials [5]. For most patients, this is clinically insignificant. For patients with known tachyarrhythmias, persistent sinus tachycardia, or atrial flutter, the increase warrants cardiology review before starting therapy.

Diabetic Retinopathy and Rapid Glucose Lowering

Patients with pre-existing diabetic retinopathy who have poorly controlled type 2 diabetes face a specific concern. The SUSTAIN-6 trial (N=3,297) reported a higher rate of diabetic retinopathy complications in the semaglutide group versus placebo (3.0% vs. 1.8%, P<0.001) [10]. The FDA label for Ozempic includes a warning about this risk, stating it may be related to the rapid improvement in glycemic control rather than a direct drug effect [1].

Any patient with known moderate-to-severe non-proliferative or proliferative diabetic retinopathy should have ophthalmology clearance before starting a GLP-1 agent through any channel, including Willow.

Is Willow Legit? How to Verify Any GLP-1 Telehealth Platform

"Is Willow legit?" is the most common consumer question about this platform. Legitimacy has several layers: legal registration, prescriber licensing, pharmacy sourcing, and transparent billing.

How to Check Prescriber and Platform Credentials

Any telehealth platform operating in the United States must employ or contract with licensed physicians or advanced practice providers who hold active, unrestricted licenses in the patient's state. You can verify this in under five minutes:

1. Search your state's medical board website for the prescriber's name and license number.
2. Check whether the platform or its compounding pharmacy partner is registered with LegitScript (legitscript.com), an independent pharmacy verification service referenced by the FDA and Google for telehealth compliance.
3. Review the FDA's list of approved GLP-1 agents at accessdata.fda.gov to confirm the drug you are being prescribed matches an approved product or a legally compounded equivalent [11].

The FDA has issued multiple guidance documents and warning letters to telehealth companies dispensing compounded semaglutide, particularly as the drug shortage status has evolved. As of early 2025, the FDA removed semaglutide from its drug shortage list, which has regulatory implications for compounders [11].

What to Look for in Billing and Consent Documents

A legitimate platform will present you with a clear itemized cost before you pay, a written informed consent document that lists contraindications, and a mechanism to transfer your records to your primary care physician. Platforms that obscure monthly subscription fees, make cancellation difficult, or do not provide a written prescription summary to the patient should be treated with skepticism.

Willow Complaints: What Consumers Report

Consumer reviews on the Better Business Bureau and similar platforms for GLP-1 telehealth services, including Willow, frequently cite three recurring issues: delays between approval and prescription shipment, difficulty reaching clinical staff for follow-up questions, and confusion about what is included in the monthly fee versus add-on charges. These are operational, not necessarily clinical, concerns. They become clinical concerns when they delay dose titration, prevent reporting of adverse effects, or result in medication gaps that destabilize glucose control in diabetic patients.

The FDA's MedWatch program allows patients and providers to report adverse events from any medication or device, including those prescribed via telehealth [11]. If you experience a serious adverse event through any platform, file a MedWatch report directly with the FDA.

Drug Interactions That Require In-Person Review Before Starting GLP-1 Therapy

GLP-1 receptor agonists slow gastric emptying, which can alter the absorption of oral medications taken at the same time. This is a particular concern for:

• Oral contraceptives: Reduced absorption may lower contraceptive efficacy. The EMA's assessment of oral semaglutide (Rybelsus) noted a modest reduction in ethinylestradiol Cmax when taken simultaneously [12]. The interaction with injectable GLP-1 agents is considered less pronounced but not zero.
• Levothyroxine: Absorption is sensitive to co-administration with other drugs. Patients on thyroid hormone replacement should take levothyroxine at least 30 to 60 minutes before any meal or other medication, and should have TSH rechecked 6 to 8 weeks after starting a GLP-1 agent.
• Warfarin and narrow therapeutic index drugs: Slowed gastric motility may alter absorption timing unpredictably. Patients on warfarin should have INR monitored more frequently after starting GLP-1 therapy [13].

A telehealth intake that does not conduct a full medication reconciliation cannot reliably catch all of these interactions.

Pediatric and Adolescent Patients

The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in adolescents aged 12 and older with BMI at or above the 95th percentile for age and sex in December 2022 [11]. This approval came with specific titration requirements and monitoring expectations that differ from adult protocols.

Willow's platform is designed primarily for adult women. Patients aged <18 should not attempt to enroll in an adult-oriented telehealth GLP-1 platform. Their care should be coordinated through a pediatric endocrinologist or an adolescent medicine specialist who can manage age-appropriate titration and monitor for growth effects.

Mental Health History and Suicidal Ideation

The FDA issued a notice in 2023 stating it was investigating reports of suicidal ideation and self-harm in patients using GLP-1 receptor agonists, primarily semaglutide and liraglutide [11]. A subsequent FDA review and a large Nordic pharmacoepidemiological study published in The BMJ (N=107,000+) found no statistically significant increase in suicidal behavior attributable to GLP-1 agents compared to other anti-obesity or diabetes medications [14].

Still, patients with a recent history of suicidal ideation or active major depressive disorder should disclose this history to their prescriber. An async telehealth form is not equipped to conduct a validated depression screen (such as the PHQ-9) or a suicide risk assessment. The American Association of Clinical Endocrinology recommends that providers inquire about mental health history before initiating obesity pharmacotherapy [6].

Practical Pre-Enrollment Checklist for Willow Candidates

Before completing a Willow intake form, review the following:

• Personal or family history of medullary thyroid carcinoma or MEN2 (absolute contraindication per FDA label [1])
• Current pregnancy, plans to conceive within two months, or active breastfeeding
• History of acute or chronic pancreatitis
• Active or recent eating disorder diagnosis (within 12 months)
• eGFR <30 mL/min/1.73m² or active dialysis
• Known diabetic retinopathy (moderate or severe)
• Tachyarrhythmia or recent cardiac intervention with prescribing restrictions
• Use of warfarin, narrow therapeutic index medications, or oral contraceptives
• Age <18

If any of the above apply, the correct first step is a conversation with a specialist, not enrollment in a cash-pay telehealth platform.